
Sign up to save your podcasts
Or


Hey! Down Round is running a sale on premium membership. Sign up in the next week using this link, and you can get an annual membership for $49 instead of the usual $70.
This week we're talking about the much-hyped weight loss drug Ozempic and its producer, Danish pharma giant Novo Nordisk. Thanks to the crazy success of Ozempic, Novo Nordisk is now literally the biggest company in Europe by market cap. Now the vultures are circling, and a whole bunch of drugmakers are rushing competitors to market.
We talk about the drug, the company, it's weirdly 'techy' marketing and where it fits into the incoming universe of biotech and pharma tech.
Links
See omnystudio.com/listener for privacy information.
By Down Round4.8
99 ratings
Hey! Down Round is running a sale on premium membership. Sign up in the next week using this link, and you can get an annual membership for $49 instead of the usual $70.
This week we're talking about the much-hyped weight loss drug Ozempic and its producer, Danish pharma giant Novo Nordisk. Thanks to the crazy success of Ozempic, Novo Nordisk is now literally the biggest company in Europe by market cap. Now the vultures are circling, and a whole bunch of drugmakers are rushing competitors to market.
We talk about the drug, the company, it's weirdly 'techy' marketing and where it fits into the incoming universe of biotech and pharma tech.
Links
See omnystudio.com/listener for privacy information.

1,981 Listeners

8,850 Listeners

271 Listeners

591 Listeners

266 Listeners

576 Listeners

283 Listeners

970 Listeners

315 Listeners

611 Listeners

21 Listeners

25 Listeners

306 Listeners

198 Listeners

110 Listeners